China is working on the reform of the review and assessment system to register drugs, in order to approach international standards in this discipline and speed up the entry of new and better products into the national healthcare system, the senior official said.
He also referred to the challenges of the process and was open to strengthening cooperation with the Cuban regulatory authority and the biopharmaceutical industry, in order to exchange on the main changes the reform will imply, the official note states.
Bi made the statements after receiving the island’s ambassador here, Miguel Angel Ramirez, at the CFDA headquarters.
Among other issues, the two sides highlighted the sustained process of development of the Cuban biotechnology and the consensus reached by the governments from both countries to deepen ties in this area.
Cuba and China founded the Changchun Heber Biological Technology joint venture in 2003 in the northeastern province of Jilin. The main objective is to manufacture biotechnological products.